<p>MiRNA-124 inhibits the proliferation, migration and invasion of cancer cell in hepatocellular carcinoma by downregulating lncRNA-UCA1</p>

Abstract

Purpose: It has been reported that miRNA-124 inhibits hepatocellular carcinoma (HCC) progression, while lncRNA-UCA1 promotes HCC. The aim of this study is to find whether miRNA-124, as a tumor suppressor in HCC can inhibit lncRNA-UCA1 in HCC cell. Methods: Tumor tissues and adjacent healthy tissues were obtained from 66 patients diagnosed with HCC in Binzhou Medical University Hospital from January 2011 to January 2013. Cell proliferation assay, in vitro cell migration and invasion assay were applied for the research. Results: In the present study we found that miRNA-124 was downregulated, while lncRNA-UCA1 was upregulated in tumor tissues comparing to adjacent healthy tissues of HCC patients. Expression of miRNA-124 and lncRNA-UCA1 in tumor tissues were not affected by HBV or HCV infection. Analysis of followed-up data revealed that low miRNA-124 level and high lncRNA-UCA1 level were closely correlated with poor survival. Overexpression of miRNA-124 led to inhibited lncRNA-UCA1 expression in cells of HCC cell lines, while overexpression of lncRNA-UCA1 failed to significantly affect miRNA-124 expression. Expression levels of miRNA-124 and lncRNA-UCA1 were inversely and significantly correlated in tumor tissues but not in adjacent healthy tissues. Overexpression of miRNA-124 led to inhibited, while overexpression of lncRNA-UCA1 led to increased proliferation, migration and invasion rates of HCC cell lines. In addition, lncRNA-UCA1 overexpression attenuated the inhibitory effects of miRNA-124 overexpression on cancer cell proliferation, migration and invasion. Conclusion: Therefore, miRNA-124 may inhibit the proliferation, migration and invasion of cancer cell in hepatocellular carcinoma by downregulating lncRNA-UCA1.

<p>MIR22HG As A Tumor Suppressive lncRNA In HCC: A Comprehensive Analysis Integrating RT-qPCR, mRNA-Seq, And Microarrays</p>

“…1 Hepatocellular carcinoma (HCC) is the predominant type of liver cancer and accounts for approximately 80% of liver cancer. 2 In the past decade, the incidence and mortality of HCC has shown an upward trend in both males and females. 3 Current treatment options for HCC patients include surgical resection, local ablation, and chemotherapy, and these have achieved certain therapeutic effects.…”

Integrative analysis of dysregulated lncRNA-associated ceRNA network reveals potential lncRNA biomarkers for human hepatocellular carcinoma

“…These lncRNAs were primarily associated with tumor grade, TNM stage, and lymphatic metastasis in HCC. Among these 26 lncRNAs, MCM3AP-AS1, UCA1, AKR7L, C3P1, AKR1C6P, LINC01018, and A1BG-AS1 have been reported in lymphatic metastasis and invasion and are diagnostic biomarkers for HCC (Praml, Savelyeva & Schwab, 2003;Wang et al, 2006;Zhang, Luo & Zhang, 2019;Zhao et al, 2019a;Zhao et al, 2019b;Zhao et al, 2019c;Zheng et al, 2015). However, other lncRNAs are not yet associated with HCC progression.…”

“…Closely related dysregulated lncRNAs may assist in identifying valuable biomarkers for the diagnosis and prognosis of HCC. Current studies of HCC and lncRNAs have mainly focused on sequencing small tissue samples and cell lines (Tan et al, 2019;Zhao et al, 2019a;Zhao et al, 2019b;Zhao et al, 2019c). Large sample population studies are rarely reported.…”

Identification of Prognostic Biomarkers and Correlation with Immune Infiltrates in Hepatocellular Carcinoma Based on a Competing Endogenous RNA Network

“…An increasing body of evidence has demonstrated that dysregulated miRNAs play a crucial role in the initiation, progression, and therapy of various tumors [4,28,34]. Baolei et al revealed that miRNA-124 is a negative regulator of HCC with respect to proliferation and invasion by downregulating lncRNA-UCA1 [35]. Baltruskeviciene E et al found that downregulated expression of miRNA-148a and miRNA-625-3p is related to tumor budding in colorectal cancer, and EMT was considered a possible molecular mechanism [36].…”